Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 30 of the 38 sources its claims cite were checked for support.

Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study

Open access
Xie, Lu, Xu, Jie, Sun, Xin, Liu, Kuisheng, Sun, Kunkun, Li, Yuan, Liu, Rong, Wang, Du, Shao, Shurong, Chen, Zhongjiang, Pang, Zheng, Zhou, Guangxin, Wu, Sujia, Hua, Yingqi, Hu, Haiyan, Wei, Ran, Yang, Yi, Ji, Tao, Guo, Wei, Tang, Xiaodong · 2025 · Nature Communications

Published version of a preprint

Abstract

Relapsed or refractory osteosarcoma carries a poor prognosis after standard chemotherapy. We conducted a multicenter, randomized, phase II trial (NCT05277480) to compare apatinib plus ifosfamide/etoposide (IE) with IE alone in patients who had progressed following at least one prior line of chemotherapy. Patients were randomized 2:1 to receive apatinib (500 mg orally once daily) plus IE (ifosfamide 1.8 g/m²/day and etoposide 100 mg/m²/day, days 1–3 every 3 weeks) or IE alone (same doses, days 1–5 every 3 weeks). The primary endpoint was progression-free survival (PFS). Between April 14, 2022, and August 22, 2023, 81 patients were enrolled (53 in apatinib plus IE group and 28 in IE group). After a median follow-up of 19.9 months, the median PFS was 5.5 months (95% confidence interval [CI]: 3.9, 6.4) with apatinib plus IE compared with 3.4 months (95% CI: 1.4, 4.6) with IE (hazard ratio, 0.60; 95% CI: 0.37, 0.98; P = 0.0402). The trial met its pre-specified primary endpoint. These results suggest that apatinib plus IE may improve PFS in relapsed or refractory osteosarcoma, but as a randomized phase II study, the findings are exploratory and require confirmation in phase III trials. In patients with metastatic osteosarcoma who have progressed on first-line chemotherapy, the prognosis is poor. Here, the authors report a phase II randomized clinical trial comparing the combination of apatinib (multi tyrosine kinase inhibitor) and chemotherapy (ifosfamide and etoposide) against chemotherapy alone in patients with relapsed or refractory metastatic osteosarcoma.

Overview

CoChat Summary

TL;DR

In this randomized phase II trial, adding apatinib to ifosfamide/etoposide significantly prolonged progression-free survival versus ifosfamide/etoposide alone in patients with advanced osteosarcoma that had progressed after prior chemotherapy. The authors describe the findings as exploratory and requiring phase III confirmation, with no overall survival benefit observed.

Key findings

  • Median PFS was 5.5 months (95% CI 3.9–6.4) with apatinib plus IE versus 3.4 months (95% CI 1.4–4.6) with IE alone (HR 0.60; 95% CI 0.37–0.98; P = 0.0402), meeting the primary endpoint.
  • Median OS was 18.1 months (95% CI 13.7–25.2) with apatinib plus IE versus 22.9 months (95% CI 19.3–NE) with IE alone (HR 1.48; 95% CI 0.76–2.89; nominal P = 0.2493).
  • ORR was 32.1% versus 25.0% (P = 0.6126), and DCR was 90.6% versus 60.7% (P = 0.0026).
  • Grade ≥3 TRAEs occurred in 69.8% of the apatinib plus IE group versus 64.3% of the IE group; SAEs occurred in 11.3% versus 10.7%.

Methods

  • Multicenter, randomized, open-label phase II trial conducted at four centers in China (NCT05277480); 81 patients were enrolled 2:1 to apatinib plus IE (n = 53) or IE alone (n = 28).
  • Eligible patients were aged 12–65 years with histologically/pathologically confirmed locally advanced or metastatic high-grade osteosarcoma progressing after at least one prior chemotherapy line, measurable by RECIST 1.1.
  • Treatment: apatinib 500 mg orally once daily plus ifosfamide 1.8 g/m²/day and etoposide 100 mg/m²/day on days 1–3 every 3 weeks, versus the same ifosfamide/etoposide doses on days 1–5 every 3 weeks. Primary endpoint was investigator-assessed PFS; Kaplan-Meier, log-rank test, and Cox proportional hazards models were used.

Limitations

  • The authors state that no biomarker analysis was included, that apatinib plus IE was not compared with apatinib monotherapy or apatinib plus anti-PD-1 therapy, and that the open-label design plus differences in chemotherapy dose intensity may have biased patient-reported QoL assessments.
  • The authors also emphasize that this was an exploratory phase II trial: PFS was lower than anticipated, EFS did not reach statistical significance when local therapy was counted as an event (HR 0.64; 95% CI 0.40–1.02; nominal P = 0.0598), and no OS benefit was observed.
  • The text makes evident additional limitations: the sample size was small, multiple comparisons were not adjusted for, and protocol-disallowed local therapies occurred in some patients, complicating interpretation of PFS/EFS.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-025-65467-8

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Patient flowchart. FAS, full analysis set, SS, safety analysis set. Source data are provided as a Source Data file.
Fig. 1 Patient flowchart. FAS, full analysis set, SS, safety analysis set. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 2 Swimming plot for both groups. Treatment exposure and duration of response in the (A) Apa+IE group and (B) IE group. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not estimable. Source data are provided as a Source Data file.
Fig. 2 Swimming plot for both groups. Treatment exposure and duration of response in the (A) Apa+IE group and (B) IE group. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not estimable. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 3 The Kaplan-Meier curves for survival in both groups at investigators’ evaluation. Kaplan-Meier curves of (A) progression-free survival and (B) overall survival. Survival outcomes were estimated using the Kaplan-Meier method and compared between groups with the two-sided log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using the Cox proportional hazards model. NE, not estimable. Source data are provided as a Source Data file.
Fig. 3 The Kaplan-Meier curves for survival in both groups at investigators’ evaluation. Kaplan-Meier curves of (A) progression-free survival and (B) overall survival. Survival outcomes were estimated using the Kaplan-Meier method and compared between groups with the two-sided log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using the Cox proportional hazards model. NE, not estimable. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

15 Valid · 0 Not valid · 4 Not checked · 55 Own results and interpretations

31 more claims · 4 with their cited sources checked

Create a free account to see all 74 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 30
  • Probably not a substantial claim. 17

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 19 references

Cited by

See all 3

Metadata

Authors
Xie, L., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Liu, R., Wang, D., Shao, S., Chen, Z., Pang, Z., Zhou, G., Wu, S., Hua, Y., Hu, H., Wei, R., Yang, Y., Ji, T., Guo, W., & Tang, X.
Affiliations
  • Peking University People's Hospital (CN)
  • Nanjing General Hospital of Nanjing Military Command (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
  • Guo, Wei
  • Tang, Xiaodong
Venue
Nature Communications
Published
2025-11-25
Volume
16
Issue
1
Pages
10473-10473
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4416631760
Cited by
3
References
19
Citations by year
2026: 3
FWCI
1.95
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • Research Square (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Peking University
  • Peking University People's Hospital
  • National Science and Technology Major Project
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
osteosarcoma, apatinib, ifosfamide, etoposide, metastatic osteosarcoma, tyrosine kinase inhibitors, progression-free survival, second-line chemotherapy, combination chemotherapy
MeSH terms
Progression-Free Survival, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Etoposide, Female, Humans, Ifosfamide, Male, Middle Aged, Pyridines, Osteosarcoma, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study. https://app.cochat.ai/papers/10.1038/s41467-025-65467-8
The paper
Xie, L., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Liu, R., Wang, D., Shao, S., Chen, Z., Pang, Z., Zhou, G., Wu, S., Hua, Y., Hu, H., Wei, R., Yang, Y., Ji, T., Guo, W., & Tang, X. (2025). Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study. Nature Communications. https://doi.org/10.1038/s41467-025-65467-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.